Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

586 articles

Research Review

Showing 1–1 of 1 articles · Keyword: siMOB1A Clear keyword

Journal of ovarian research2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Microfluidic lipid nanoparticles co-delivering siMOB1A and paclitaxel for ovarian cancer therapy

Xu Jy, Liu K, Chen Ly, Liu C, Chen Dy, Wu Sg, Et Al.

Ovarian cancer is the foremost cause of mortality among gynecologic malignancies. Paclitaxel (PTX) exerts a significant therapeutic effect on ovarian cancer by targeting microtubules and impeding the cell cycle progression during the mitosis phase. MOB kinase activator 1 A (MOB1A) has been proven to regulate the…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.